Nestlé S.A. (NESN)
SIX Swiss · Vevey, Switzerland · Founded 1866 · CEO Philipp Navratil
Valuation summary
$99.82 fair value versus $95.43 in the market, a difference of +4.6%. Rated Hold.
| Fair value per share | $99.82 |
| Current share price | $95.43 |
| Upside / downside | +4.6% |
| Bear case | $55.60 |
| Bull case | $166.04 |
| Discount rate (WACC) | 7.6% |
| Terminal growth | 2.10% |
| Market capitalisation | $243B |
| EV / Sales | 2.9x |
About Nestlé S.A.
Founded in 1866 by Henri Nestlé, a German pharmacist in Vevey, Switzerland, who developed an infant formula for babies unable to breastfeed. Philipp Navratil became CEO in 2025. Nestlé is the largest food company in the world, with over 2,000 brands: Nescafé and Nespresso in coffee, KitKat, Purina pet food, Gerber baby food, Maggi, San Pellegrino and Perrier waters, and a health science division selling medical nutrition. Pet care and coffee are the two most attractive parts of the portfolio. Prices quoted in Swiss francs.
Investment case
- Purina pet care is a genuinely excellent business — pet ownership is rising and owners do not trade down on pet food.
- Nespresso and Nescafé give exposure to coffee, one of the few staples categories with real premiumisation.
- Swiss franc reporting and a defensive portfolio make it a low-volatility holding.
Key risks
- Organic growth has been persistently below its own targets and management credibility has suffered.
- Coffee and cocoa input costs surged and passing them through has cost volume.
- The portfolio is arguably too broad, with several underperforming categories management has been slow to exit.
Recent developments
- 2026-10-22 · Q3 organic growth picks up to 4% and the 2026 organic sales growth outlook of 3% to 4% is maintained source
Revenue by segment
| Powdered & Liquid Beverages | 28% |
| PetCare (Purina) | 21% |
| Nutrition & Health Science | 17% |
| Prepared Dishes & Confectionery | 20% |
| Milk products & Water | 14% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $108.2B | $14.5B |
| Year 2 | $111.4B | $15.4B |
| Year 3 | $114.7B | $16.3B |
| Year 4 | $118.2B | $17.2B |
| Year 5 | $121.7B | $18.3B |
What the street says
A restructuring story rather than a growth story. The debate is whether new management will divest aggressively enough to re-rate the shares.
Comparable companies: HD · PEP · SBUX · OR · MDLZ · MC · MAR · LOW
Open the interactive model, price chart and sensitivity grid →